Celery Seed Extract for Health & Longevity - Quick Reference Sheet

Celery Seed Extract for Health & Longevity

Created on 10/19/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Celery seed extract is an oral botanical supplement used for blood pressure and metabolic health. Clinical trials strongly support lowering elevated blood pressure, with moderate evidence for reducing uric acid, anxiety, and depressive symptoms and improving female sexual function. Triglycerides decline without cholesterol or lasting blood sugar benefits. Short-term adverse event rates match placebo, alongside allergy, sunlight skin reaction, drug interaction, and rodent male fertility risks. (Full Review)

Protocol

Standardized high-potency vascular protocol
1,340 mg/day (670 mg twice daily)
Oral capsules standardized to 85% 3-n-butylphthalide (3nB) for overt hypertension (~141/92 mmHg)
Integrative standardized low-dose protocol
150 mg/day (75 mg twice daily)
Standardized to 85% phthalides for metabolic syndrome (<140/90 mmHg), slow CYP3A4/CYP2D6 metabolizers, or concurrent medications
Best time of day
With breakfast and dinner (spaced 12 hours apart)
Dietary lipids enhance lipophilic phthalide absorption; split dosing matches the 5.33-hour 3nB half-life (or 500 mg three times daily for 1,500 mg/day whole-seed powder)
Time to effect
Blood Pressure Reduction
Within 4 weeks
Systolic (-11 mmHg) and diastolic (-8 mmHg) blood pressure, anxiety, and short-term fasting glucose reductions at 1,340 mg/day
Serum Uric Acid Reduction
By 12 weeks
Serum uric acid (-35.7 µmol/L [-0.60 mg/dL]) and fasting triglyceride reductions at 150 mg/day
Female Sexual Function Improvement
By 6 weeks
Total Female Sexual Function Index (FSFI) desire, arousal, lubrication, and pain score improvements at 1,500 mg/day (500 mg three times daily)

Benefits

Contraindications
  • Individuals with documented allergy to celery, celeriac, carrot (Apiaceae family), birch pollen, or mugwort pollen
  • Pregnant or breastfeeding women
  • Individuals with uncontrolled renal disease (serum creatinine above the upper limit of normal) or active kidney inflammation
  • Individuals with hepatic disease or elevated liver transaminases (ALT or aspartate aminotransferase [AST, liver enzyme] above the upper limit of normal)
  • Patients scheduled for upcoming elective surgical procedures
Key Interactions
  • Antihypertensives (calcium channel blockers [amlodipine], angiotensin-converting enzyme inhibitors [lisinopril], angiotensin II receptor blockers [losartan], and diuretics [hydrochlorothiazide])
  • CYP3A4, CYP2D6, and cytochrome P450 2A6 (CYP2A6) substrates (atorvastatin, metoprolol, nicotine)
  • Prescription anticoagulants and over-the-counter antiplatelets (warfarin, aspirin)
  • Over-the-counter analgesics and sedatives (acetaminophen/paracetamol, diphenhydramine)
  • Prescription photosensitizing medications and thyroid hormone (doxycycline, levothyroxine)
  • Supplements with hypotensive or antiplatelet activity (aged garlic extract, omega-3 fish oil)
  • Phototherapy and ultraviolet tanning interventions (UVA tanning beds, psoralen-UVA photochemotherapy)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Mild gastrointestinal and dermatologic discomfort, severe allergic cross-reactivity, furanocoumarin-induced phototoxicity
  • Speculative: High-dose spermatogenesis inhibition, reactive metabolite hepatotoxicity

Monitoring

Marker Target Why
Seated or 24-hour ambulatory blood pressure (SBP / DBP) No established target; track reduction from the individual's own baseline Marker the intervention is expected to change (efficacy) and safety check against hypotension
Serum uric acid 3.5–7.2 mg/dL (208–428 µmol/L) in men; 2.6–6.0 mg/dL (155–357 µmol/L) in women (standard reference range) Marker the intervention is expected to change via xanthine oxidase (XO) inhibition
Fasting serum triglycerides (TG) No established target; track reduction from the individual's own baseline Marker the intervention is expected to change
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ALT: 7–56 U/L; AST: 8–33 U/L (standard reference range) Safety check for reactive 3nB sulfate metabolite stress and marker of hepatic response
Serum creatinine and blood urea nitrogen (BUN) Creatinine: 0.6–1.3 mg/dL; BUN: 7–20 mg/dL (standard reference range) Safety check for renal clearance of 3nB metabolites and marker improved in hypertensive trials

Cadence: Baseline 7-day home seated/standing blood-pressure log (or 24-hour ambulatory monitor) and fasting morning blood draw; home seated/standing blood pressure recorded daily for the first 2 weeks and weekly thereafter; fasting lab panel repeated at 4 weeks, 12 weeks, and every 6 months.

Qualitative Assessment

  • Orthostatic tolerance and dizziness: Tracking lightheadedness upon standing during the first 14 days detects excessive vasodilation early.
  • Perceived anxiety and mood stability: Subjective calmness or repeated Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) questionnaires at baseline and week 4 assess mood response.
  • Joint comfort and morning stiffness: Daily joint discomfort logs on a 0–10 scale over 12 weeks track symptom response in individuals with uric-acid elevation or osteoarthritis.
  • Oral, skin, and digestive tolerance: Observing for oral itching, rash after sun exposure, or upper abdominal discomfort after doses identifies intolerance early.